BioCorRx Inc
OTC:BICX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioCorRx Inc
Free Cash Flow
BioCorRx Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioCorRx Inc
OTC:BICX
|
Free Cash Flow
-$2.3m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Universal Health Services Inc
NYSE:UHS
|
Free Cash Flow
$849.2m
|
CAGR 3-Years
48%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
2%
|
|
|
Encompass Health Corp
NYSE:EHC
|
Free Cash Flow
$439.2m
|
CAGR 3-Years
53%
|
CAGR 5-Years
8%
|
CAGR 10-Years
2%
|
|
|
Tenet Healthcare Corp
NYSE:THC
|
Free Cash Flow
$2.5B
|
CAGR 3-Years
99%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
30%
|
|
|
HCA Healthcare Inc
NYSE:HCA
|
Free Cash Flow
$7.7B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Ensign Group Inc
NASDAQ:ENSG
|
Free Cash Flow
$370.7m
|
CAGR 3-Years
55%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
BioCorRx Inc
Glance View
BioCorRx, Inc. engages in the provision of alcoholism and opioid addiction treatment. The company is headquartered in Anaheim, California. The company went IPO on 2010-08-31. The firm's BioCorRx Recovery Program is a non-addictive, medication-assisted treatment (MAT) program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application. The company is also engaged in the research and development of sustained release naltrexone products for the treatment of addiction and other possible disorders. Its products include BICX101 and BICX104. Its lead candidate, BICX101, is a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The company is also developing an implantable naltrexone treatment, BICX104, a long-acting naltrexone implant that can last several months for the treatment of opioid dependence and alcohol use disorders. Its subsidiary is BioCorRx Pharmaceuticals, Inc.
See Also
What is BioCorRx Inc's Free Cash Flow?
Free Cash Flow
-2.3m
USD
Based on the financial report for Dec 31, 2025, BioCorRx Inc's Free Cash Flow amounts to -2.3m USD.
What is BioCorRx Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-1%
Over the last year, the Free Cash Flow growth was -110%. The average annual Free Cash Flow growth rates for BioCorRx Inc have been -4% over the past three years , -1% over the past five years .
